Selected News from Today's FirstWord

Merck & Co. halts development of experimental Parkinson's disease drug preladenant

Merck & Co. on Thursday announced that it is discontinuing the clinical programme for its investigational Parkinson's disease drug preladenant because a preliminary review of data from three Phase III Full story

• Phase III study finds Novo Nordisk's liraglutide results in 8-percent average weight loss - (Ref. Novo Nordisk; Chicago Tribune; FOX News)
• Elan rejects Royalty Pharma's raised offer - (Ref. Business Wire; PR Newswire; Yahoo!Finance; StreetInsider; The Sunday Business Post; NASDAQ; Interactive Investor; Morningstar)
• Forest Laboratories CEO to retire by year's end - (Ref. Business Wire; Bloomberg; StreetInsider; NASDAQ; CNBC)
• Johnson & Johnson to seek approval for more than 10 new products by 2017 - (Ref. SmartMoney; Bloomberg; Chicago Tribune; FOX Business; StreetInsider)

Also in the News

• Products:
• doxorubicin,
• melphalan,
• pexastimogene devacirepvec,
• Rayaldy,
• SB 9200,
• topiramate,
• UC1010

• Companies:
• Aeterna Zentaris,
• Biogen Idec,
• Karolinska Development,
• Merck & Co.,
• Merrimack Pharmaceuticals,
• OncoGenex,
• Pharming

• Markets:
• Australia,
• France,
• India

Most Read Stories in the Past Week

• Novartis CEO discusses plans for Diovan patent expiration
• Pfizer records 5-percent rise in second-quarter profit
• Pfizer may introduce OTC version of Lipitor, sources say
• NICE provisionally rejects Novartis' oral MS drug Gilenya
• HHS drops case against Forest CEO